Cover Image

PP 1.22 - 00120 Suppression of CD4+ T-cell-intrinsic immunity by HIV-1 latency-reversing HDACi

Saved in:

Bibliographic Details
Main Authors:	J. Kazmierski (Author), D. Postmus (Author), E. Wyler (Author), C. Fischer (Author), K. Meixenberger (Author), L. Loyal (Author), A. Thiel (Author), N. Bannert (Author), M. Landthaler (Author), C. Goffinet (Author)
Format:	Book
Published:	Elsevier, 2022-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Mixed effects of HDACi on host gene expression and their implications for HIV reactivation from latency
by: N. Beliakova-Bethell, et al.
Published: (2015)

36 Dose-dependent effects of HDACi on T cell activation and HIV latency reversal
by: X.T. Kuang, et al.
Published: (2016)

PP 1.1 - 00009 TB-associated microenvironment promotes HIV latency in CD4+ T cells
by: G. Duette, et al.
Published: (2022)

PP 3.10 - 00168 Vpr synergizes with vorinostat to prevent HIV-1 latency establishment
by: C. Lewis, et al.
Published: (2022)

HDACiDB: a database for histone deacetylase inhibitors
by: Murugan K, et al.
Published: (2015)

PP 1.33 - 00167 Integrated single-cell multi-omic profiling of HIV latency reversal
by: A. Manickam, et al.
Published: (2022)

Lysosome activable polymeric vorinostat encapsulating PD-L1KD for a combination of HDACi and immunotherapy
by: Fengkun Lu, et al.
Published: (2021)

PP 1.4 - 00037 Histone decrotonylation uniquely regulates HIV-1 transcription and can be modulated to control HIV-1 latency
by: T.L. Simermeyer, et al.
Published: (2022)

PP 5.4 - 00184 Optimization of Smac Mimetics as HIV-1 Latency Reversing Agents
by: L. Pache, et al.
Published: (2022)

PP 1.11 - 00075 Selective nuclear retention of spliced and unspliced HIV-1 mRNAs following latency reversal
by: E. Honeycutt, et al.
Published: (2022)

PP 5.1 - 00045 Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Long-Acting Lenacapavir for Treatment of HIV
by: N. Shaik, et al.
Published: (2022)

Hepatic myeloid sarcoma preceding acute megakaryoblastic leukemia with t(1;22) in an infant: Case report
by: Zeynep Canan Özdemir, et al.
Published: (2016)

PP 1.10 - 00069 Isotretinoin enhances IL-15 mediated HIV latency reversal and reduces the inducible latent reservoir
by: J. Howard, et al.
Published: (2022)

PP 1.39 - 00086 The level of cell activation is associated with the pre-integrative latency of HIV linear DNA
by: H.M. Roux, et al.
Published: (2022)

Influence of sex as an intrinsic biological variable in a primary cell model of HIV latency
by: A.B. Macedo, et al.
Published: (2017)

PP 1.3 - 00022 Signaling pathways that activate P-TEFb to reverse HIV latency in CD4+ T cells
by: U. Mbonye, et al.
Published: (2022)

PP 2.7 - 00093 Modeling HIV-1 Pathogenesis and Latency in iPSC-Derived Human Cerebral Organoids
by: J. Crater, et al.
Published: (2022)

20 Sirtuin1 inhibitor nicotinamide disrupts HIV-1 latency
by: S. Samer, et al.
Published: (2016)

10 The interferon-inducible restriction factor TRIM22 contributes to HIV-1 latency
by: F. Turrini, et al.
Published: (2016)

24 Thalidomide reverses latency of HIV-1 provirus
by: S. Samer, et al.
Published: (2016)

Galectin-1 promotes HIV-1 latency reactivation
by: J. Rubione, et al.
Published: (2019)

The HIV-1 antisense transcript AST is an inducer of viral latency
by: F. Romerio, et al.
Published: (2015)

PP 2.9 - 00125 Impact of latency reversal agents on estrogen receptor alpha gene and protein expression
by: C. Ceriani, et al.
Published: (2022)

PP 1.36 - 00182 Effect of HIV-1C Transmitted/Founder Viruses 5'LTRand tat Genetic Variation on Viral Reservoir Size and Latency Reversal Potential
by: Shreyal Maikoo, et al.
Published: (2022)

Population Pharmacokinetics of CC-122
by: Cheng Y, et al.
Published: (2021)

Cellular modulation and HIV reactivation in response to serial treatment of latently HIV infected CD4 T cells with histone deacetylase inhibitors (HDACi)
by: J. Maxwell, et al.
Published: (2019)

PP 2.3 - 00034 CD8+ T-Cell Sieving During SIV Reactivation from Latency
by: S. Docken, et al.
Published: (2022)

Degradation of the XPB subunit of TFIIH by spironolactone reduces HIV-1 reactivation from latency
by: L. Mori, et al.
Published: (2019)

PP 2.8 - 00124 Spironolactone Represses HIV-1 Driven Transcription in Human Microglia and T cell Models of Latency and Alters DNA Methylation of Metabolic Genes
by: A. Pang, et al.
Published: (2022)

The unique enrichment of histone modifications and its relationship with HIV-1 latency in some chromosomes
by: K.C. Kim, et al.
Published: (2015)

HIV-1 transcriptional latency in resting CD4 T-cell
by: M. Benkirane
Published: (2015)

Optimisation of Smac mimetics as HIV-1 latency reversing agents
by: L. Pache, et al.
Published: (2019)

PP 4.22 - 00087 Reversal of exhaustion of HIV-1-specific CTLs by CRISPR-mediated disruption of PD-1 gene
by: C. Baez, et al.
Published: (2022)

Design, synthesis, molecular docking study, and biological evaluation of salicylaldimine derivatives as potential histone deacetylases inhibitors (HDACi) and anticancer agents
by: Heba M. Hesham, et al.
Published: (2018)

Developing an in vitro model for HIV-1 latency in Tfh cells using tonsillar tissue
by: B. Luttge, et al.
Published: (2017)

Latency reactivating agents: impact on human macrophages physiology and susceptibility to HIV-1 infection
by: L. Hany, et al.
Published: (2019)

PP 1.28 - 00156 The HIV-1 antisense RNA Ast promotes viral latency via epigenetic silencing of the proviral 5'LTR and is expressed in latently infected cells from ART-suppressed donors
by: F. Romerio, et al.
Published: (2022)

PP 2.13 - 00160 Enhancing Tolerability and Efficacy of Latency Reversing Agents in "Kick and Kill" HIV Cure Approaches
by: J. Moran, et al.
Published: (2022)

38 Small molecule inhibitors of BAF; a new family of compounds in HIV-1 latency reversal
by: E. De Crignis, et al.
Published: (2016)

Human endogenous retrovirus expression landscape in models of HIV-1 latency
by: M. de Mulder Rougvie, et al.
Published: (2019)